STRO

Sutro Biopharma, Inc. (NASDAQ:STRO) is a clinical-stage biotechnology company founded in 2003 and headquartered in South San Francisco, California. Originally incorporated as Fundamental Applied Biology, Inc., the company went public in September 2018. Sutro specializes in developing protein therapeutics for cancer and autoimmune disorders using its proprietary cell-free protein synthesis platform called XpressCF+. The company focuses on creating antibody-drug conjugates (ADCs) and other targeted therapies, with multiple drug candidates currently in clinical trials.